Drug Patents owned by Biogen Idec

1. List of Spinraza drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7101993 BIOGEN IDEC Oligonucleotides containing 2′-O-modified purines
Sep, 2023

(6 months from now)

US7838657 BIOGEN IDEC Spinal muscular atrophy (SMA) treatment via targeting of SMN2 splice site inhibitory sequences
Jul, 2027

(4 years from now)

US8361977 BIOGEN IDEC Compositions and methods for modulation of SMN2 splicing
May, 2030

(7 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8110560 BIOGEN IDEC Spinal muscular atrophy (SMA) treatment via targeting of SMN2 splice site inhibitory sequences
Dec, 2025

(2 years from now)

US10266822 BIOGEN IDEC Spinal muscular atrophy (SMA) treatment via targeting of SMN2 splice site inhibitory sequences
Dec, 2025

(2 years from now)

US9717750 BIOGEN IDEC Compositions and methods for modulation of SMN2 splicing in a subject
Jun, 2030

(7 years from now)

US8980853 BIOGEN IDEC Compositions and methods for modulation of SMN2 splicing in a subject
Nov, 2030

(7 years from now)

US9926559 BIOGEN IDEC Compositions and methods for modulation of SMN2 splicing in a subject
Jan, 2034

(10 years from now)

US10436802 BIOGEN IDEC Methods for treating spinal muscular atrophy
Sep, 2035

(12 years from now)

Exclusivity Exclusivity Expiration
Orphan Drug Exclusivity (ODE) Dec 23, 2023

Drugs and Companies using NUSINERSEN SODIUM ingredient

Market Authorisation Date: 23 December, 2016

Treatment: Treatment of spinal muscular atrophy; Treatment of spinal muscular atrophy by inhibiting an smn2 pre-mrna intronic splicing silencer site; Treatment of spinal muscular atrophy by increasing exon-7 inclusion in smn2 mrna; Treatment of type iii spinal muscular atrophy; Treatment of type ii spinal muscular atrophy; Treatment of infantile-onset spinal muscular atrophy

Dosage: SOLUTION;INTRATHECAL

More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic

Other things you might be interested in